Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Cardiovascular disease (CVD) is increasingly recognized as a chronic, progressive condition affecting multiple vascular beds.
• Patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) form a high-risk subset with elevated event rates and reduced survival.
• Optimal management strategies for this polyvascular disease population are evolving.

Purpose of the Study:

• To review current evidence and guidelines for managing antithrombotic and lipid-lowering therapies in patients with polyvascular disease.
• To highlight the need for tailored treatment approaches based on individual patient risk profiles.
• To address the current limitations in data specific to this patient group.

Main Methods:

• Literature review of recent pharmacological advancements in antithrombotic and lipid-lowering therapies.
• Analysis of clinical trial data and expert consensus relevant to patients with combined CAD and PAD.
• Synthesis of current indications and therapeutic combinations.

Main Results:

• Recent pharmacological advances enable diverse therapeutic combinations for antithrombotic and lipid-lowering treatments.
• Individualized treatment optimization is necessary, considering patient-specific risk profiles.
• Existing data specifically addressing the management of polyvascular disease patients remain limited.

Conclusions:

• Effective management of polyvascular disease necessitates a personalized approach to antithrombotic and lipid-lowering drug selection.
• Further research is needed to refine treatment strategies and improve outcomes for patients with concomitant CAD and PAD.
• Optimizing pharmacotherapy is key to mitigating the increased cardiovascular risk in this population.